Novasep, a supplier of services and technologies for the life sciences industry, has announced a €6m ($6.8m) investment at its Chasse-sur-Rhône site, France. The investment is planned to increase and modernise its manufacturing capabilities to support production of APIs, in areas such as oncology, central nervous system (CNS) and infectious diseases.
Flow chemistry is one of Novasep's main current areas of focus, with the establishment of a research platform in flow chemistry at its Chasse-sur-Rhône site back in 2013 to develop methodologies for efficient process development under continuous flow conditions, using both internal chemical and engineering expertise. This recent investment is aimed to strengthen these capacities, with the installation of a cGMP flow reactor to support the needs of pharmaceutical companies.
In parallel, the company continues to increase its capabilities on the site for low to medium volume APIs in response to increased customer demand. These investments are planned to accommodate customers’ growing needs for outsourced API manufacturing services, increasing flexibility and reinforcing technologies.
This investment project has been selected and supported by the French government as part of the ‘France Relance’ recovery plan. The programme aims to reinforce production capabilities of APIs for essential therapies, increasing economic growth and boosting employment.
“The addition of a cGMP flow capability at manufacturing scale, a technology which Novasep has been working on for several years in R&D, is an important step forward to strengthen our competitiveness in the Active Pharmaceutical Ingredients market. We are proud of this investment which will increase employment opportunities in France whilst improving responsiveness and reinforcing manufacturing capacities for essential therapeutic drugs for our customers, and ultimately for patients”, said Catherine Vindevoghel, Site Director of Chasse-sur-Rhône.